0001140361-16-060261.txt : 20160405 0001140361-16-060261.hdr.sgml : 20160405 20160405163544 ACCESSION NUMBER: 0001140361-16-060261 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160405 DATE AS OF CHANGE: 20160405 EFFECTIVENESS DATE: 20160405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sapience Therapeutics, Inc. CENTRAL INDEX KEY: 0001661731 IRS NUMBER: 475419141 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-260695 FILM NUMBER: 161554975 BUSINESS ADDRESS: STREET 1: 73 MARKET STREET STREET 2: SUITE 376 CITY: YONKERS STATE: NY ZIP: 10710 BUSINESS PHONE: 914-226-3432 MAIL ADDRESS: STREET 1: 73 MARKET STREET STREET 2: SUITE 376 CITY: YONKERS STATE: NY ZIP: 10710 D 1 primary_doc.xml X0707 D LIVE 0001661731 Sapience Therapeutics, Inc. 2 Overhill Road Scarsdale NY NEW YORK 10583 914-607-6931 DELAWARE None None Corporation true 2015 Barry Kappel, Ph.D. 2 Overhill Road Scarsdale NY NEW YORK 10583 Executive Officer Director Isaac Blech 2 Overhill Road Scarsdale NY NEW YORK 10583 Director David Scheinberg, Ph.D. 2 Overhill Road Scarsdale NY NEW YORK 10583 Director Robert Ruffolo, Ph.D. 2 Overhill Road Scarsdale NY NEW YORK 10583 Director Howard Pien 2 Overhill Road Scarsdale NY NEW YORK 10583 Director Biotechnology Decline to Disclose 06b false true false true false 50000 Maxim Group LLC 12078 None None 405 Lexington Avenue New York NY NEW YORK 10174 All States false 22500000 0 22500000 false 0 800000 0 The Placement Agent is entitled to a fee of 8% of funds raised in the Offering by investors introduced to the Company. 0 false Sapience Therapeutics, Inc. /s/ Barry Kappel Barry Kappel Chief Executive Officer 2016-04-05